Hepatic Manifestations of Cystic Fibrosis

Clin Liver Dis. 2019 May;23(2):263-277. doi: 10.1016/j.cld.2018.12.008. Epub 2019 Feb 21.

Abstract

Cystic fibrosis liver disease (CFLD) remains the third leading cause of death in patients with cystic fibrosis. Although most patients with CFLD present in childhood, recent studies suggest a second wave of liver disease in adulthood. There are no clear guidelines for diagnosing CFLD. Treatment options for CFLD remain limited, and while UDCA is widely used, its long-term benefit is unclear. Those who develop hepatic decompensation or uncontrolled variceal bleeding may benefit from liver transplant, either alone, or in combination with lung transplant.

Keywords: CFLD; Cystic fibrosis liver disease; Focal biliary cirrhosis; Liver disease in cystic fibrosis; Non-cirrhotic portal hypertension.

Publication types

  • Review

MeSH terms

  • Cholagogues and Choleretics / therapeutic use
  • Cystic Fibrosis / complications*
  • Cystic Fibrosis / genetics
  • Diagnosis, Differential
  • Humans
  • Hypertension, Portal / diagnosis
  • Hypertension, Portal / etiology
  • Hypertension, Portal / therapy
  • Liver Diseases / complications
  • Liver Diseases / diagnosis*
  • Liver Diseases / etiology*
  • Liver Diseases / therapy
  • Liver Transplantation
  • Ursodeoxycholic Acid / therapeutic use

Substances

  • Cholagogues and Choleretics
  • Ursodeoxycholic Acid